KDV B — Kdventures AB Share News
0.000.00%
Last trade - 00:00- SEK185.53m
- SEK138.12m
- SEK1.67m
Brief: Karolinska Development's Portfolio Company Ossdsign Signs Long-Term Contract With Hospital Network In France
Brief: Karolinska Development Q4 Net Profit Swings To Loss Of SEK 19.5 Mln
Brief: Karolinska Development Raises About SEK 378 Mln Before Transaction Costs In Rights Issue
Brief: Karolinska Development's Umecrine Cognition Presents Preclinical Data On Golexanolone
Brief: Karolinska Development's Svenska Vaccinfabriken Appoints Richard Bethell As New CEO
Brief: Karolinska Development Proposes Rights Issue
Brief: Karolinska Development Q3 Net Loss Narrows To SEK 1.2 Mln
Brief: Karolinska Development Says Organon Acquires Forendo Pharma
Brief: Karolinska Development's Unit To Collaborate With University College London
Brief: Karolinska Development's Portfolio Company Ossdsign Receives Expanded FDA Market Clearance For Ossdsign Cranial PSI
Brief: Karolinska Development Q2 Net Profit Rises To SEK 216.4 Mln
Brief: Ossdsign Launches Synthetic Bone Graft Catalyst In US - Karolinska
Brief: Karolinska Development: Positive Phase 2 Results For Eprenetapopt
Brief: Karolinska Development's Portfolio Company Raises Capital Through Share Issue
Brief: Karolinska Development: Promimic Gets Market Clearance From FDA
Brief: Karolinska Development Sells Its Holding In Lipidor
Brief: Karolinska Development says Co Expands Its Portfolio Through New Investment In Anacardio
Brief: Karolinska Development AB Announces That Co, Based On External Valuation, Will Increase Book Value Of Its Holding In Portfolio Co Dilafor
Brief: Karolinska Development Portfolio Co's Eprenetapopt Reaches Primary Efficacy Endpoint In Combination Therapy Of Acute Myeloid Leukemia